Volume 1.32 | Oct 22

Human Immunology News 1.32 October 22, 2013
Human Immunology News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Human Immunology News on Twitter
Circulating Precursor CCR7loPD-1hi CXCR5+ CD4+ T Cells Indicate Tfh Cell Activity and Promote Antibody Responses upon Antigen Reexposure
Follicular B helper T (Tfh) cells support high affinity and long-term antibody responses. Here researchers found that within circulating CXCR5+ CD4+ T cells in humans and mice, the CCR7loPD-1hi subset has a partial Tfh effector phenotype, whereas CCR7hiPD-1lo cells have a resting phenotype. [Immunity]
Full Article
| Graphical Abstract
A New System for High-Throughput Cell Isolation Directly from Whole Blood
PUBLICATIONS (Ranked by impact factor of the journal)
Germline Mutations in NFKB2 Implicate the Noncanonical NF-κB Pathway in the Pathogenesis of Common Variable Immunodeficiency
To investigate the molecular cause of common variable immunodeficiency (CVID), scientists carried out exome sequence analysis of a family diagnosed with CVID and identified a heterozygous frameshift mutation, c.2564delA, in NFKB2 affecting the C terminus of NF-κB2. [Am J Hum Genet] Abstract | Press Release

Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele Upregulates IL10 Expression
Scientists assessed 19 tag SNPs, covering the interleukin-10 (IL10) gene cluster including IL19, IL20 and IL24, for association with systemic lupus erythematosus (SLE) in 15,533 case and control subjects from four ancestries. [PLoS Genet] Full Article

Basis for Fluctuations in Lymphocyte Counts in Fingolimod-Treated Patients with Multiple Sclerosis
Researchers aimed to determine the range of fluctuation in total lymphocyte counts (TLCs) in peripheral blood over a 4- to 7-year period in patients with multiple sclerosis receiving fingolimod and the relation between TLCs and T-cell subsets that are differentially regulated in the lymph nodes by fingolimod. [Neurology] Abstract

Dysregulation of Anti-Inflammatory Annexin A1 Expression in Progressive Crohn’s Disease
Researchers examined the association between annexin A1 (ANXA1) and inflammatory bowel disease (IBD), and the effects of anti-TNF-α, Infliximab, therapy on ANXA1 expression. ANXA1 and TNF-α transcript levels in PBMC were measured by RT PCR. [PLoS One] Full Article

Treatment with Anti-Tumor Necrosis Factor Biologics in Human T-Lymphotropic Virus Type 1 Positive Patients with Rheumatoid Arthritis
The authors investigated the response to and safety of anti-tumor necrosis factor (TNF) therapy in human T-lymphotropic virus type 1 (HTLV-1) positive patients with rheumatoid arthritis (RA). The therapeutic response was evaluated in 10 HTLV-1 positive and 20 negative patients with RA at three months after the beginning of anti-TNF therapy using the European League Against Rheumatism improvement criteria. [Arthritis Care Res] Abstract

Expression Regulation of Co-Inhibitory Molecules on Human Natural Killer Cells in Response to Cytokine Stimulations
Researchers showed that the expressions of co-inhibitors on natural killer cells, including lymphocyte activation gene-3 (LAG-3), programmed death-1 (PD-1), and T cell immunoglobulin and ITIM domain, are differently regulated by cytokines interleukin (IL)-10, IL-12, IL-15, interferon-α, and tumor growth factor-β (TGF-β). Among the tested cytokines, IL-12 is the most powerful inducer of LAG-3, and TGF-β is the strongest suppresser of PD-1. [Cytokine] Abstract

Increased Frequency of Intestinal CD4+ T Cells Reactive with Mycobacteria in Patients with Crohn’s Disease
Investigators assessed the frequency of mycobacteria and Escherichia coli reactive T cells in intestinal biopsies from patients with Crohn’s disease and ulcerative colitis. [Scand J Gastroenterol] Full Article

Pollen-Induced Antigen Presentation by Mesenchymal Stem Cells and T Cells from Allergic Rhinitis
This study investigated the immune effects of mesenchymal stem cells (MSCs) on allergen-stimulated lymphocytes from allergic rhinitis (AR) subjects. In contrast to subjects with allergic asthma, MSCs caused a significant increase in the proliferation of antigen-challenged lymphocytes from AR subjects. [Clin Transl Immunol] Full Article

Subscribe to our sister publications: Immunology of Infectious Disease News and Immune Regulation News!

Free Demo: Isolate Cells in the New 96-Well EasySep™ EasyPlate Magnet
Immunosuppressive Networks and Checkpoints Controlling Antitumor Immunity and Their Blockade in the Development of Cancer Immunotherapeutics and Vaccines
This review describes the immunosuppressive mechanisms controlling antitumor immunity and the novel strategies being employed to design effective immunotherapeutics against tumors based on inhibition of suppressor cells or blockade of immune checkpoints to allow induction of more potent effector T cell responses. [Oncogene] Abstract

T-Lymphocyte Recognition of Beta Cells in Type 1 Diabetes: Clinical Perspectives
The characterization of antigenic fragments – peptides – recognized by T-cells paves the way towards new assays for predicting type 1 diabetes (T1D) and its prevention using antigen- or peptide-specific immunotherapy, while avoiding side effects that may counteract the limited efficacy of immunosuppression and immunomodulation in preserving β-cells from autoimmune destruction in recent-onset T1D patients. [Diabetes Metab] Abstract

Visit our reviews page to see a complete list of reviews in the human immunology research field.
immatics Closes €34 Million Financing to Complete Phase III Development of IMA901 for Renal Cancer
immatics biotechnologies GmbH announced that it has closed a €34 million Series D financing round. The new funds will enable immatics to conclude the development of its lead vaccine IMA901, including completing all of the activities necessary to prepare for regulatory filings in the US and Europe. IMA901 – a cancer vaccine comprising ten different tumor-associated peptides that are found to be highly over-expressed in the majority of patients suffering from renal cell carcinoma – is in a pivotal Phase III trial. [immatics biotechnologies GmbH] Press Release

Stallergenes to Exercise Option to Develop and Commercialize a Birch Allergy New Product
Stallergenes S.A. and DBV Technologies announced that they have entered into a research and development agreement for the treatment of birch allergy. This collaboration is the first agreement following their previously announced collaboration focused on developing innovative treatments for respiratory allergies. [Stallergenes S.A.] Press Release

Key Antibody Patent Granted in Japan
Cellmid Limited advises that the Japanese Patent Office granted Cellmid’s patent application JP 2007-544236 “Method for Treatment or Prevention of Diseases Associated with a Functional Disorder of Regulatory T Cells”. [Cellmid Limited] Press Release

From our sponsor: Learn how ex vivo models drive progress in HIV research. Read the research profiles.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Keystone Symposia: Molecular Cell Biology of Macrophages in Human Diseases
February 9-14, 2014
Santa Fe, United States

NEW American Academy of Allergy, Asthma & Immunology (AAAAI) 2014 Annual Meeting
February 28-March 4, 2014
San Diego, United States

Visit our events page to see a complete list of events in the human immunology community.
NEW Postdoctoral Research Position – Immunology (Singapore Immunology Network [SIgN])

Research Fellow – Cellular Immunity in Type 1 Diabetes (King’s College London)

Postdoctoral Fellow – Immunotherapy (Washington University School of Medicine)

PhD Fellowship – Chronic Vagus Nerve Stimulation as Therapy for Colitis (KU Leuven)

Postdoctoral Position – Autoimmunity (University of Chicago)

PhD Research Position – Immune Tolerance and Autoimmunity (Weizmann Institute of Science)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Human Immunology News?
Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Human Immunology News: Archives | Events | Contact Us